Most recently, Kareem served as Chief Transformation Officer at GeneDx and was responsible for driving corporate strategy, corporate development, and emerging business initiatives to further accelerate the company’s growth. Prior to that, he served as Chief Strategy Officer at Sema4, leading the development of their long-term plan, spearheading their capital formation efforts, and eventually helping to take the company public in 2021 before leading the merger with GeneDx to transform the company into a leading rare disease diagnostic testing company.

Gary is responsible for Neo’s strategy regarding its most important asset — its people. Cultivating an engaging culture focused on how the company works in support of all teammates and customers is critical to the company’s success.

Nathan is the Vice President of Medical Services and the Medical Director for the NeoGenomics North Carolina laboratory. He joined NeoGenomics as the Director of Molecular Pathology Services in 2023, before taking on this current role in August 2024. Prior to joining NeoGenomics, he was a molecular pathologist and medical director at Tempus Laboratories and, prior to that, Director of Molecular Hematopathology at the University of North Carolina.

Warren Stone was appointed President and Chief Operating Officer of NeoGenomics in April 2025. He joined Neo in November 2022 as President, Clinical Services and later became Chief Commercial Officer.

Warren is a highly accomplished enterprise leader with extensive global experience in the life science and diagnostic sectors, who most recently served as President of Americas at Ortho Clinical Diagnostics (now QuidelOrtho).